{"parse":{"title":"Toxgnostics","pageid":42887965,"revid":849171505,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"plainlinks metadata ambox ambox-content ambox-multiple_issues compact-ambox\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ambox_important.svg/40px-Ambox_important.svg.png\" width=\"40\" height=\"40\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ambox_important.svg/60px-Ambox_important.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ambox_important.svg/80px-Ambox_important.svg.png 2x\" data-file-width=\"40\" data-file-height=\"40\" /></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\"><div class=\"mw-collapsible\" style=\"width:95%; margin: 0.2em 0;\"><b>This article has multiple issues.</b> Please help <b><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Toxgnostics&amp;action=edit\">improve it</a></b> or discuss these issues on the <b><a href=\"/wiki/Talk:Toxgnostics\" title=\"Talk:Toxgnostics\">talk page</a></b>. <small><i>(<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove these template messages</a>)</i></small>\n<div class=\"mw-collapsible-content\" style=\"margin-top: 0.3em;\">\n      <table class=\"plainlinks metadata ambox ambox-content\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ambox_important.svg/40px-Ambox_important.svg.png\" width=\"40\" height=\"40\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ambox_important.svg/60px-Ambox_important.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b4/Ambox_important.svg/80px-Ambox_important.svg.png 2x\" data-file-width=\"40\" data-file-height=\"40\" /></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">This article <b>may document a <a href=\"/wiki/Wikipedia:NEO\" class=\"mw-redirect\" title=\"Wikipedia:NEO\">neologism</a> or <a href=\"/wiki/Protologism\" title=\"Protologism\">protologism</a> in such a manner as to promote it</b>.<span class=\"hide-when-compact\"> Please add <a href=\"/wiki/Wikipedia:RS\" class=\"mw-redirect\" title=\"Wikipedia:RS\">more reliable sources</a> to establish its current use and the impact the term has had on its field. Otherwise consider <a href=\"/wiki/Wikipedia:Moving_a_page\" title=\"Wikipedia:Moving a page\">renaming</a> or deleting the article.</span>  <small><i>(January 2015)</i></small><small class=\"hide-when-compact\"><i> (<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>\n<table class=\"plainlinks metadata ambox ambox-content ambox-Primary_sources\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><a href=\"/wiki/File:Question_book-new.svg\" class=\"image\"><img alt=\"Question book-new.svg\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png\" width=\"50\" height=\"39\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/75px-Question_book-new.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/100px-Question_book-new.svg.png 2x\" data-file-width=\"512\" data-file-height=\"399\" /></a></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">This article <b>relies too much on <a href=\"/wiki/Wikipedia:Verifiability\" title=\"Wikipedia:Verifiability\">references</a> to <a href=\"/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources\" title=\"Wikipedia:No original research\">primary sources</a></b>.<span class=\"hide-when-compact\"> Please improve this  by adding <a href=\"/wiki/Wikipedia:No_original_research#Primary,_secondary_and_tertiary_sources\" title=\"Wikipedia:No original research\">secondary or tertiary sources</a>.</span>  <small><i>(January 2015)</i></small><small class=\"hide-when-compact\"><i> (<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>\n<table class=\"plainlinks metadata ambox ambox-style ambox-essay-like\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/40px-Edit-clear.svg.png\" width=\"40\" height=\"40\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/60px-Edit-clear.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/80px-Edit-clear.svg.png 2x\" data-file-width=\"48\" data-file-height=\"48\" /></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">This article <b>is written like a <a href=\"/wiki/Wikipedia:NOTESSAY\" class=\"mw-redirect\" title=\"Wikipedia:NOTESSAY\">personal reflection or opinion essay</a></b> that states a Wikipedia editor's personal feelings about a topic.<span class=\"hide-when-compact\"> Please <a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Toxgnostics&amp;action=edit\">help improve it</a> by rewriting it in an <a href=\"/wiki/Wikipedia:Encyclopedic_style\" class=\"mw-redirect\" title=\"Wikipedia:Encyclopedic style\">encyclopedic style</a>.</span>  <small><i>(January 2015)</i></small><small class=\"hide-when-compact\"><i> (<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>\n    </div>\n</div><small class=\"hide-when-compact\"><i> (<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>\n<p><b>Toxgnostics</b> is part of <a href=\"/wiki/Personalized_medicine\" title=\"Personalized medicine\">Personalized medicine</a> as it describes the guiding principles for the discovery of <a href=\"/wiki/Pharmacogenomic\" class=\"mw-redirect\" title=\"Pharmacogenomic\">pharmacogenomic</a> biomarker tests, also referred to as <a href=\"/wiki/Companion_diagnostic\" title=\"Companion diagnostic\">companion diagnostic</a> tests, which identify if an individual patient is likely to suffer severe drug toxicity from treatment with a specific therapeutic agent. Once at risk individuals are identified drug toxicity can be prevented using elective dose reduction or prescription of an alternative medication.<sup id=\"cite_ref-Toxgnostics_1-0\" class=\"reference\"><a href=\"#cite_note-Toxgnostics-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Background\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Background</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Toxgnostic_principles\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Toxgnostic principles</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Regulatory_oversight_of_toxgnostic_tests\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Regulatory oversight of toxgnostic tests</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#References\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Background\">Background</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Toxgnostics&amp;action=edit&amp;section=1\" title=\"Edit section: Background\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The majority of toxgnostic studies have been candidate gene studies restricted to the known Absorption, Distribution, Metabolism, and Excretion genes (<a href=\"/wiki/ADME\" title=\"ADME\">ADME</a>) of drug treated patients.  The PharmaADME consortium<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup> identified 32 core genes containing 184 variants within common pathways that should be included in ADME candidate gene studies of toxicity biomarkers. Toxicity biomarkers that have been clinically validated using this restricted panel of genes include the <a href=\"/w/index.php?title=P450_cytochrome&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"P450 cytochrome (page does not exist)\">P450 cytochrome</a> assay that is currently recommended for routine clinical use of the oral anticoagulant warfarin. Using <a href=\"/wiki/Next-generation_sequencing\" class=\"mw-redirect\" title=\"Next-generation sequencing\">next-generation sequencing</a> methods and <a href=\"/wiki/Genome-wide_association_studies\" class=\"mw-redirect\" title=\"Genome-wide association studies\">genome-wide association studies</a> a more comprehensive toxgnostic approach can be utilized through unbiased analysis of several million variants across the whole human genome, including introns and exons, for pharmacogenomic markers of drug induced toxicity.<sup id=\"cite_ref-Toxgnostics_1-1\" class=\"reference\"><a href=\"#cite_note-Toxgnostics-1\">&#91;1&#93;</a></sup>\n</p><p>Cancer drugs have been highlighted as particularly appropriate candidates for toxgnostic studies due to the significant toxicity profiles associated with both targeted therapies<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup> and chemotherapy.<sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup> Most cancer patients obtain only modest benefit from treatment, whereas toxicity is common and often associated with severe side effects which include considerable morbidity and mortality. One of the most commonly used chemotherapy drugs <a href=\"/wiki/5-fluorouracil\" class=\"mw-redirect\" title=\"5-fluorouracil\">5-fluorouracil</a> (5FU) prescribed as <a href=\"/wiki/Adjuvant_therapy\" title=\"Adjuvant therapy\">adjuvant therapy</a> following surgical resection of early stage <a href=\"/wiki/Colorectal_cancer\" title=\"Colorectal cancer\">colorectal cancer</a> benefits only approx. 4% of patients, whereas 30\u201340% of those treated will suffer severe toxicity such as <a href=\"/wiki/Neutropenia\" title=\"Neutropenia\">neutropenia</a>, <a href=\"/wiki/Mucositis\" title=\"Mucositis\">mucositis</a>, <a href=\"/wiki/Hand-foot_syndrome\" class=\"mw-redirect\" title=\"Hand-foot syndrome\">hand-foot syndrome</a>, <a href=\"/wiki/Diarrhoea\" class=\"mw-redirect\" title=\"Diarrhoea\">diarrhoea</a>, and <a href=\"/wiki/Stomatitis\" title=\"Stomatitis\">stomatitis</a>, fatal toxicities will kill 0.5-1% of people treated.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup> Through the use of toxgnostic screens a number of genetic variants have now been identified that can be used to predict 5FU toxicity prior to treatment.<sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup> These genetic variants can be used to identify the individuals predisposed to severe drug toxicity and the dose of 5FU chemotherapy can be reduced to prevent severe toxic side effects. Toxgnostic biomarker tests currently available for use in clinical practice include markers for <a href=\"/wiki/Irinotecan\" title=\"Irinotecan\">irinotecan</a>, <a href=\"/wiki/Thioguanine\" class=\"mw-redirect\" title=\"Thioguanine\">thioguanine</a>, <a href=\"/wiki/Warfarin\" title=\"Warfarin\">warfarin</a> and <a href=\"/wiki/5FU\" class=\"mw-redirect\" title=\"5FU\">5FU</a>.\n</p>\n<h2><span class=\"mw-headline\" id=\"Toxgnostic_principles\">Toxgnostic principles</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Toxgnostics&amp;action=edit&amp;section=2\" title=\"Edit section: Toxgnostic principles\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Toxgnostic studies are defined by four key elements:<sup id=\"cite_ref-Toxgnostics_1-2\" class=\"reference\"><a href=\"#cite_note-Toxgnostics-1\">&#91;1&#93;</a></sup>\n</p>\n<ol><li>Analysis should be embedded within large, prospective, randomized, controlled clinical trials (i.e. <a href=\"/wiki/Phase_III_clinical_trials\" class=\"mw-redirect\" title=\"Phase III clinical trials\">Phase III clinical trials</a>)</li>\n<li>The phenotype of interest should be clinically relevant and clearly defined using internationally standardized criteria and systematically captured such as the US <a href=\"/wiki/National_Cancer_Institute\" title=\"National Cancer Institute\">National Cancer Institute</a> (NCI) <a href=\"/wiki/Common_Terminology_Criteria_for_Adverse_Events\" title=\"Common Terminology Criteria for Adverse Events\">Common Terminology Criteria for Adverse Events</a> (CTCAE) grade 3\u20135 toxicity.</li>\n<li>Analysis should be unbiased to encompass the maximum relevant genomic diversity, rather than being limited by what is often a superficial understanding of the pathways involved in the <a href=\"/wiki/Pharmacokinetics\" title=\"Pharmacokinetics\">pharmacokinetics</a> and <a href=\"/wiki/Pharmacodynamics\" title=\"Pharmacodynamics\">pharmacodynamics</a> of the agent.</li>\n<li>The performance of individual variants should be compared with that of a combined risk score, which may outperform each individual variant when they are analysed separately.</li></ol>\n<p>Appropriate analytical approaches for toxgnostic studies include <a href=\"/wiki/Candidate_gene\" title=\"Candidate gene\">candidate gene</a> studies, <a href=\"/wiki/Genome-wide_association_study\" title=\"Genome-wide association study\">GWAS</a> and <a href=\"/wiki/Whole_genome_sequencing\" title=\"Whole genome sequencing\">whole genome sequencing</a>. GWAS and whole genome sequencing are the most comprehensive approaches though careful considerations must be applied to the relevance, analysis and interpretation of the results to prevent over-fitting, which produces false-positive results, a proposed GWAS workflow is shown below.<sup id=\"cite_ref-Toxgnostics_1-3\" class=\"reference\"><a href=\"#cite_note-Toxgnostics-1\">&#91;1&#93;</a></sup>\n</p>\n<div class=\"center\"><div class=\"thumb tnone\"><div class=\"thumbinner\" style=\"width:581px;\"><a href=\"/wiki/File:Toxgnostic_GWAS_discovery_pathway.png\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/a/a6/Toxgnostic_GWAS_discovery_pathway.png\" width=\"579\" height=\"453\" class=\"thumbimage\" data-file-width=\"579\" data-file-height=\"453\" /></a>  <div class=\"thumbcaption\">Proposed clinical trial paradigm for discovery of toxgnostics markers through GWAS.</div></div></div></div>\n<h2><span class=\"mw-headline\" id=\"Regulatory_oversight_of_toxgnostic_tests\">Regulatory oversight of toxgnostic tests</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Toxgnostics&amp;action=edit&amp;section=3\" title=\"Edit section: Regulatory oversight of toxgnostic tests\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Toxicity biomarkers can be co-developed and co-approved with the respective drug as a <a href=\"/w/index.php?title=Companion_diagnostic_test&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Companion diagnostic test (page does not exist)\">companion diagnostic test</a>, this requires <a href=\"/wiki/Premarket_approval\" class=\"mw-redirect\" title=\"Premarket approval\">premarket approval</a> (PMA). The <a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">Food and Drug Administration</a> (FDA) IVD Companion Diagnostic Device guidance issued in draft 14 July 2011 states that a companion diagnostic test can be used to \u201cIdentify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic product\u201d.<sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup> Additionally there are guidleines for the submission of pharmacogenomic studies from the FDA<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup> and draft guidance from the <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a> (EMA).<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Toxgnostics&amp;action=edit&amp;section=4\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap mw-references-columns\"><ol class=\"references\">\n<li id=\"cite_note-Toxgnostics-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Toxgnostics_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Toxgnostics_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Toxgnostics_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Toxgnostics_1-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\">Church D, Kerr R, Domingo E, Rosmarin D, Palles C, Maskell K, Tomlinson I, Kerr D (2014). \"'Toxgnostics': an unmet need in cancer medicine\". Nat Rev Cancer (6):440-5. doi:10.1038/nrc3729. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/24827503\">24827503</a>.</span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\">Johnson R, Newport R, Kerr R, Kerr DJ (2014). \"Toxgnostics:predicting and preventing chemotherapy-induced side effects.\" Personalised Medicine 11 (7):683-685. doi:10.2217/pme.14.56</span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.medscape.com/viewarticle/830384Kerr\">DJ Kerr. \"Chemo Safety: Can Biomarkers Help?\". Medscape Oncology, Kerr on Oncology. 28 August 2014.</a></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.pharmaadme.org/joomla/\">PharmaADME consortium. Michael S. Phillips Ph.D. Retrieved 30 Dec 2014.</a></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\">Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A (2007). \"Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers\". Oncologist (12):1443\u20131455.<a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18165622\">18165622</a></span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\">Walko CM, McLeod H (2009). \"Pharmacogenomic progress in individualized dosing of key drugs for cancer patients\". Nature Clinical Practice Oncology (6):153-162.\ndoi:10.1038/ncponc1303.</span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\">Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr, DJ (2007)\"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.\" Lancet 370: 2020\u20132029. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18083404\">18083404</a>.</span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\">Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, Domingo E, Jones A, Howarth K, Freeman-Mills L, Johnstone E, Wang H, Love S, Scudder C, Julier P, Fern\u00e1ndez-Rozadilla C, Ruiz-Ponte C, Carracedo A, Castellvi-Bel S, Castells A, Gonzalez-Neira A, Taylor J, Kerr R, Kerr D, Tomlinson I (2014). Gut. doi: 10.1136/gutjnl-2013-306571. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/24647007\">24647007</a></span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf\">\"Draft Guidance for Industry and Food and Drug Administration Staff\"</a> <span style=\"font-size:85%;\">(PDF)</span><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2014-06-13</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Draft+Guidance+for+Industry+and+Food+and+Drug+Administration+Staff&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FMedicalDevices%2FDeviceRegulationandGuidance%2FGuidanceDocuments%2FUCM262327.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AToxgnostics\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20090901130414/http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126957.pdf\">\"Archived copy\"</a> <span style=\"font-size:85%;\">(PDF)</span>. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126957.pdf\">the original</a> <span style=\"font-size:85%;\">(PDF)</span> on 2009-09-01<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2008-08-27</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Archived+copy&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2Fregulatoryinformation%2Fguidances%2Fucm126957.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AToxgnostics\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/01/WC500160232.pdf\">\"Guidance\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>www.ema.europa.eu</i>. 10 January 2014.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.ema.europa.eu&amp;rft.atitle=Guidance&amp;rft.date=2014-01-10&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FScientific_guideline%2F2014%2F01%2FWC500160232.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AToxgnostics\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n\n<!-- \nNewPP limit report\nParsed by mw1301\nCached time: 20180911144337\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.152 seconds\nReal time usage: 0.213 seconds\nPreprocessor visited node count: 1121/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 34168/2097152 bytes\nTemplate argument size: 8869/2097152 bytes\nHighest expansion depth: 16/40\nExpensive parser function count: 3/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 7716/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.052/10.000 seconds\nLua memory usage: 2.27 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  170.432      1 -total\n 57.48%   97.959      4 Template:Ambox\n 49.87%   84.998      1 Template:Multiple_issues\n 45.27%   77.160      1 Template:Reflist\n 25.25%   43.029      3 Template:Cite_web\n 13.05%   22.245      1 Template:Neologism\n 11.65%   19.847      4 Template:PMID\n  9.58%   16.322      4 Template:Catalog_lookup_link\n  4.15%    7.079      1 Template:Essay-like\n  3.77%    6.429      1 Template:Primary_sources\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:42887965-0!canonical and timestamp 20180911144337 and revision id 849171505\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"Articles_about_possible_neologisms_from_January_2015"},{"sortkey":"","hidden":"","*":"Articles_lacking_reliable_references_from_January_2015"},{"sortkey":"","hidden":"","*":"All_articles_lacking_reliable_references"},{"sortkey":"","hidden":"","*":"Wikipedia_articles_with_style_issues_from_January_2015"},{"sortkey":"","hidden":"","*":"All_articles_with_style_issues"},{"sortkey":"","hidden":"","*":"Articles_with_multiple_maintenance_issues"},{"sortkey":"","*":"Genomics"},{"sortkey":"","*":"Toxicology"}],"links":[{"ns":14,"exists":"","*":"Category:Articles about possible neologisms from January 2015"},{"ns":14,"exists":"","*":"Category:Articles lacking reliable references from January 2015"},{"ns":14,"exists":"","*":"Category:Wikipedia articles with style issues from January 2015"},{"ns":0,"exists":"","*":"5-fluorouracil"},{"ns":0,"exists":"","*":"5FU"},{"ns":0,"exists":"","*":"ADME"},{"ns":0,"exists":"","*":"Adjuvant therapy"},{"ns":0,"exists":"","*":"Candidate gene"},{"ns":0,"exists":"","*":"Colorectal cancer"},{"ns":0,"exists":"","*":"Common Terminology Criteria for Adverse Events"},{"ns":0,"exists":"","*":"Companion diagnostic"},{"ns":0,"exists":"","*":"Diarrhoea"},{"ns":0,"exists":"","*":"European Medicines Agency"},{"ns":0,"exists":"","*":"Food and Drug Administration"},{"ns":0,"exists":"","*":"Genome-wide association studies"},{"ns":0,"exists":"","*":"Genome-wide association study"},{"ns":0,"exists":"","*":"Hand-foot syndrome"},{"ns":0,"exists":"","*":"Irinotecan"},{"ns":0,"exists":"","*":"Mucositis"},{"ns":0,"exists":"","*":"National Cancer Institute"},{"ns":0,"exists":"","*":"Neutropenia"},{"ns":0,"exists":"","*":"Next-generation sequencing"},{"ns":0,"exists":"","*":"Personalized medicine"},{"ns":0,"exists":"","*":"Pharmacodynamics"},{"ns":0,"exists":"","*":"Pharmacogenomic"},{"ns":0,"exists":"","*":"Pharmacokinetics"},{"ns":0,"exists":"","*":"Phase III clinical trials"},{"ns":0,"exists":"","*":"Premarket approval"},{"ns":0,"exists":"","*":"Protologism"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Stomatitis"},{"ns":0,"exists":"","*":"Thioguanine"},{"ns":0,"exists":"","*":"Warfarin"},{"ns":0,"exists":"","*":"Whole genome sequencing"},{"ns":0,"*":"P450 cytochrome"},{"ns":0,"*":"Companion diagnostic test"},{"ns":1,"exists":"","*":"Talk:Toxgnostics"},{"ns":4,"exists":"","*":"Wikipedia:Encyclopedic style"},{"ns":4,"exists":"","*":"Wikipedia:Moving a page"},{"ns":4,"exists":"","*":"Wikipedia:NEO"},{"ns":4,"exists":"","*":"Wikipedia:NOTESSAY"},{"ns":4,"exists":"","*":"Wikipedia:No original research"},{"ns":4,"exists":"","*":"Wikipedia:RS"},{"ns":4,"exists":"","*":"Wikipedia:Verifiability"},{"ns":12,"exists":"","*":"Help:Maintenance template removal"}],"templates":[{"ns":10,"exists":"","*":"Template:Multiple issues"},{"ns":10,"exists":"","*":"Template:Ambox"},{"ns":10,"exists":"","*":"Template:Neologism"},{"ns":10,"exists":"","*":"Template:Primary sources"},{"ns":10,"exists":"","*":"Template:Essay-like"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:PMID"},{"ns":10,"exists":"","*":"Template:Catalog lookup link"},{"ns":10,"exists":"","*":"Template:Trim"},{"ns":10,"exists":"","*":"Template:Yesno-no"},{"ns":10,"exists":"","*":"Template:Yesno"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":828,"exists":"","*":"Module:Message box"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Message box/configuration"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:String"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"}],"images":["Ambox_important.svg","Question_book-new.svg","Edit-clear.svg","Toxgnostic_GWAS_discovery_pathway.png"],"externallinks":["//www.ncbi.nlm.nih.gov/pubmed/24827503","http://www.medscape.com/viewarticle/830384Kerr","http://www.pharmaadme.org/joomla/","//www.ncbi.nlm.nih.gov/pubmed/18165622","//www.ncbi.nlm.nih.gov/pubmed/18083404","//www.ncbi.nlm.nih.gov/pubmed/24647007","http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf","https://web.archive.org/web/20090901130414/http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126957.pdf","http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126957.pdf","http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/01/WC500160232.pdf"],"sections":[{"toclevel":1,"level":"2","line":"Background","number":"1","index":"1","fromtitle":"Toxgnostics","byteoffset":1192,"anchor":"Background"},{"toclevel":1,"level":"2","line":"Toxgnostic principles","number":"2","index":"2","fromtitle":"Toxgnostics","byteoffset":4571,"anchor":"Toxgnostic_principles"},{"toclevel":1,"level":"2","line":"Regulatory oversight of toxgnostic tests","number":"3","index":"3","fromtitle":"Toxgnostics","byteoffset":6136,"anchor":"Regulatory_oversight_of_toxgnostic_tests"},{"toclevel":1,"level":"2","line":"References","number":"4","index":"4","fromtitle":"Toxgnostics","byteoffset":7574,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Toxgnostics","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q23583432"}]}}